To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

The POISE-3 Trial: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2022

The POISE-3 Trial: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Vol: 224| Issue: 2| Number:1| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Tranexamic Acid in Patients Undergoing Noncardiac Surgery

N Engl J Med. 2022 Apr 2.

Contributing Authors:
PJ Devereaux M Marcucci TW Painter D Conen V Lomivotrov DI Sessler MTV Chan FK Borges MJ Martinez-Zapata CY Wang D Xavier SN Ofori M Wang S Efremov G Landoni YV Kleinlugtenbelt W Szczeklik D Schmartz AX Garg TG Short M Wittmann CS Meyhoff M Amir D Torres A Patel E Duceppe K Ruetzler JL Parlow V Tandon E Fleischmann CA Polanczyk A Lamy SV Astrakov WK Wu K Bhatt M de Nadal VV Likhvantsev P Paniagua HJ Aguado RP Whitlock MH McGillion M Prystajecky J Vincent J Eikelboom I Copland K Balasubramanian A Turan SI Bangdiwala D Stillo P Gross T Cafaro P Alfonsi PS Roshanov EP Belley-Côté J Spence T Richards T VanHelder W McIntyre G Guyatt S Yusuf K Leslie POISE-3 Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

9535 patients undergoing non-cardiac surgery were randomized to receive tranexamic acid (n=4757) or placebo (n=4778) at the start and end of surgery. The primary efficacy outcome was a composite bleeding outcome of life-threatening bleeding, major bleeding, or bleeding into a critical organ. The primary safety outcome was a composite endpoint of myocardial injury, non-hemorrhagic stroke, periphera...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.